Bristol-Myers Squibb Email Format
Pharmaceutical Manufacturing
・
10,001-25,000 employees
・
Lawrence Township, NJ, USA
Bristol-Myers Squibb is a global biopharmaceutical company that discovers, develops, and delivers innovative medicines in oncology, hematology, immunology, cardiovascular disease, and fibrosis.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@bms.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
1887
Headquarters
Lawrence Township, NJ, USA
Revenue
$25B-$50B
FUNDING Stage
Public
Website
Key Executives
Chris Boerner, PhD (Board Chair and Chief Executive Officer), David Elkins (Executive Vice President and Chief Financial Officer), Karin Shanahan (Executive Vice President, Chief Supply Chain & Operations Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Bristol-Myers Squibb?
Bristol-Myers Squibb uses the first.last format, so Jane Smith would be jane.smith@bms.com.
What are Bristol-Myers Squibb's core therapeutic areas in 2026?
Bristol-Myers Squibb focuses on five core therapeutic areas: oncology, hematology, immunology, cardiovascular, and neuroscience, supported by drug platforms such as bispecifics, CAR T cell therapies, and targeted protein degradation.
How does Camzyos fit into Bristol-Myers Squibb's cardiovascular portfolio?
Camzyos (mavacamten) is Bristol-Myers Squibb's treatment for symptomatic obstructive hypertrophic cardiomyopathy and is one of the fastest-growing products in its Growth Portfolio, generating $314 million in worldwide revenue in Q1 2026, up 97% year over year.
Who is the CEO of Bristol-Myers Squibb?
Chris Boerner, PhD, has served as Board Chair and Chief Executive Officer of Bristol-Myers Squibb since November 2023 and April 2024, respectively. Tools like Clay can help you find and verify the right contact at Bristol-Myers Squibb for outreach.
Where does Bristol-Myers Squibb conduct its oncology and CAR T cell research?
Bristol-Myers Squibb runs major R&D hubs in Cambridge, MA, Seattle, WA, San Diego, CA, and Boudry, Switzerland, where teams work on oncology, CAR T cell therapies like Breyanzi, and antibody-drug conjugates across its approximately 38,137-person global organization.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating